Institute of Cancer Biology and Drug Discovery, Taipei Medical University, 250 Wu-Shin St., Taipei, Taiwan.
FASEB J. 2013 Aug;27(8):3209-16. doi: 10.1096/fj.12-227132. Epub 2013 May 2.
Thyroid hormone induces tumor cell and blood vessel cell proliferation via a cell surface receptor on heterodimeric integrin αvβ3. We investigated the role of thyroid hormone-induced internalization of nuclear integrin αv monomer. Physiological concentration of thyroxine (free T4, 10(-10) M), but not 3,5,3'-triiodo-l-thyronine (T3), induced cellular internalization and nuclear translocation of integrin αv monomer in human non-small-cell lung cancer (H522) and ovarian carcinoma (OVCAR-3) cells. T4 did not complex with integrin αv monomer during its internalization. The αv monomer was phosphorylated by activated ERK1/2 when it heterodimerized with integrin β3 in vitro. Nuclear αv complexed with transcriptional coactivator proteins, p300 and STAT1, and with corepressor proteins, NCoR and SMRT. Nuclear αv monomer in T4-exposed cells, but not integrin β3, bound to promoters of specific genes that have important roles in cancer cells, including estrogen receptor-α, cyclooxygenase-2, hypoxia-inducible factor-1α, and thyroid hormone receptor β1 in chromatin immunoprecipitation assay. In summary, monomeric αv is a novel coactivator regulated from the cell surface by thyroid hormone for the expression of genes involved in tumorigenesis and angiogenesis. This study also offers a mechanism for modulation of gene expression by thyroid hormone that is adjunctive to the nuclear hormone receptor (TR)-T3 pathway.
甲状腺激素通过异二聚体整合素 αvβ3 的细胞表面受体诱导肿瘤细胞和血管细胞增殖。我们研究了甲状腺激素诱导核整合素 αv 单体内化的作用。生理浓度的甲状腺素(游离 T4,10(-10) M),而不是 3,5,3'-三碘甲状腺原氨酸(T3),诱导人非小细胞肺癌(H522)和卵巢癌(OVCAR-3)细胞中的细胞内吞和核转位。T4 在其内化过程中不与整合素 αv 单体结合。αv 单体在体外与整合素 β3 异二聚化时被激活的 ERK1/2 磷酸化。核 αv 与转录共激活蛋白 p300 和 STAT1 以及核受体共抑制蛋白 NCoR 和 SMRT 结合。T4 暴露细胞中的核 αv 单体,但不是整合素 β3,与特定基因的启动子结合,这些基因在癌细胞中具有重要作用,包括雌激素受体-α、环氧化酶-2、缺氧诱导因子-1α 和甲状腺激素受体β1 在染色质免疫沉淀测定中。总之,单体 αv 是一种新型的共激活因子,通过甲状腺激素从细胞表面调节参与肿瘤发生和血管生成的基因表达。这项研究还为甲状腺激素调节基因表达提供了一种机制,补充了核激素受体(TR)-T3 途径。